Lonza Opens New R&D Centre In Brazil
Swiss biotech firm, Lonza has inaugurated its new Salto Technology Centre (STC) in Salto, near São Paulo, Brazil.
The STC has 13 research laboratories and offers technical services and product applications, which will allow the development of customised solutions for customers in Lonza’s six business areas of biosciences, consumer health and nutrition, hygiene, coatings and composites, agro ingredients and water treatment. “With its laboratories, training/meeting rooms and support facilities, the laboratory complex will serve as a Centre of Excellence to share technologies, ingredients, diagnostic systems and knowledge used in these different business units,” a company note informed. Speaking at the opening ceremony, Lonza’s CEO Mr. Richard Ridinger said, “The new STC will join our network of Centres of Excellence around the world and enable us to share knowledge that facilitates the development of products and services aligned with the specific needs of the South American market”.
Lonza’s technology manager responsible for the project, Mr. Mauricio Franzim, informed that the initial investment in the STC was close to $2.5-mn.
2026-10-10
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
AkzoNobel Repurposes Industrial Residues into SustainableFloor Coatings
-
Color and Personal Care Giant Sensient Acquires White Biotechnology Expert Biolie to Expand Active Color Product Portfolio
-
Lonza acquires Roche US biologics facility for $1.2 billion
-
Lonza Launches Innovaform Accelerator
-
Brazil's parliament has decided that the Agriculture Ministry is solely responsible for registering pesticides
-
Brazil approved 21 registrations in the first quarter! The pesticide registration process remains lengthy
-
Lonza acquires biologics plant from Roche for $1.2 billion
-
The European Parliament has passed a gene-editing bill to further loosen regulations on gene-edited crops
-
Major Breakthrough: Xinda Biotechnology's Nylotinib Included in NCCN Guidelines for Chronic Myeloid Leukemia Treatment
-
Syngenta and Metagen strategically collaborate to accelerate biologics development in Australia
Recommend Reading
-
Advent Drops Its 2026 Purchase, and LANXESS’s €1.2 Billion Exit Plan Falls Through
-
Sun Pharma’s Organon Bid Would Redraw Indian Pharma M&A
-
AstraZeneca India Eyes ₹3,400 Crore Bengaluru Sale
-
Iran Conflict Leaves a Long Shadow on Drug Supply
-
McKinsey Pays to Close a Purdue Liability Chapter
-
Sulfate Ammonium Prices Continue to Rise in China Over the Past Ten Days (3.7-3.17)
-
What is a Surfactant? (Definition, Types, and How They Work)
-
Oxalic Acid: Acidity (pKa), Sources, and Kidney Stone Risk
-
Methanol Market Prices Fluctuate Narrowly
-
Formic Acid Shows Moving Average Crossover, Upward Momentum Limited